Kuraray Co., Ltd.

Ltt Institute Co., Ltd.

Other

Taiho Pharmaceutical Company Limited

Fuji Yakuhin Co., Ltd

Ltt Bio-pharma Co., Ltd.

Rie Igarashi

Yutaka Mizushima

Mitsuko Takenaga

Takashi Nishida

Koichi Kanehira

Michio Terasawa

Noriyuki Yamamoto

Yasuo Kosaka

Kenzo Arizono

Tetsuo Ebata

Hirofusa Ajioka

Masayuki Inoue

Keiko Hoshi

Masahito Komuro

Hiroshi Noguchi

Hiroshi Muramatsu

Akira Yanagawa

Manzo Shiono

Kunio Ando

Mutsuo Taiji

Chikao Nakayama

Tateo Nishimura

Toshitaka Kudo

Katsuo Komiya

Katsukiyo Sakurai

Ryozo Nagata

Megumu Higaki

Kayoko Hosokawa

Modified BDNF having improved pharmacological activities, pharmacokinetics and physical properties can be obtained by modifying BDNF with a 1-acyl-glycerol derivative. This BDNF being modified with a 1-acyl-glycerol derivative of the present invention has more efficacious and more excellent pharmacokinetic properties with retaining the useful effects being characteristic to BDNF which are useful as remedies for neurodegenerative diseases and diabetes mellitus, and hence, it is particularly useful as a therapeutic agent for treatment of type 2 diabetes mellitus.

Modified BDNF

A pharmaceutical preparation for intranasal administration having a better absorption rate and less irritant effects is provided. The pharmaceutical preparation comprises a mixture of a powder of an adsorbent resin and a biologically active peptide having a drug effect under the condition that they are dry prior to or after the mixing.

Pharmaceutical preparations for intranasal administration

A medicament for nasal administration to be used for disease prevention or treatment comprising a vaccine or a pharmacologically active peptide compounded with an ion exchange resin or adsorbent resin powder whose mean particle size is not larger than 200 .mu.m.

Medicaments for nasal administration

Sugar-modified interferon, modified with at least one galactose residue, which is a binding reaction product between lactose lactone and interferon is disclosed. The sugar-modified interferon, which can be obtained through simple chemical manipulation on IFN, has improved accumulating properties in the liver and enhanced physiological activities as compared with unmodified IFN.

Sugar modified interferon

Topical preparations containing cyclosporin

11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the formula ##STR1## an antiinflammatory composition thereof and a method for the production thereof. 11.beta.,17.alpha.,21-Trihydroxy-1,4-pregnadiene-3,20-dione 21-[(E,E)-3,7,11-trimethyl-2,6,10-dodecatrienoate] of the present invention exhibits remarkably excellent antiinflammatory action and besides, displays reduced side effects and can be produced in high selectivity and good yield and conveniently.

11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7,

11.beta., 17.alpha.,21-trihydroxy-1,4-pregnadiene-3,20-dione

Growing community of inventors

Kawasaki, Japan

Rie Igarashi